Global Leading Market Research Publisher QYResearch announces the release of its latest report *”Large Scale Oligonucleotide Synthesis Service – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″*. As the oligonucleotide therapeutics market accelerates—with over 15 FDA/EMA-approved antisense oligonucleotides (ASOs), siRNA, and aptamer drugs (e.g., Spinraza, Onpattro, Leqvio) and hundreds more in clinical development—the core industry challenge has shifted from discovery to commercial-scale manufacturing. Biotech CEOs, pharmaceutical R&D directors, and CDMO strategists now face a critical question: how to secure large-scale, cGMP-grade oligonucleotide synthesis capacity that can deliver kilogram quantities of high-purity, chemically modified oligos for late-stage clinical trials, commercial launch, and global supply chains. Unlike research-grade synthesis (microgram to milligram scales, non-GMP), large-scale oligonucleotide synthesis is a discrete, industrial-scale manufacturing process requiring specialized solid-phase synthesizers, high-throughput purification systems (HPLC, IEX, SEC), rigorous quality control (mass spec, HPLC, endotoxin testing), and regulatory compliance (FDA, EMA, ICH Q7). This deep-dive analysis incorporates QYResearch’s latest forecast, supplemented by 2025–2026 industry data, technology trends, and a comparative framework across gram grade and microgram grade synthesis scales, as well as across commercial and academic research applications.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5985789/large-scale-oligonucleotide-synthesis-service
Market Sizing & Growth Trajectory (Updated with 2026 Interim Data)
The global market for Large Scale Oligonucleotide Synthesis Service was estimated to be worth approximately US$ 800-1,200 million in 2025 and is projected to reach US$ 2,000-3,000 million by 2032, growing at a CAGR of 12-15% from 2026 to 2032. In the first half of 2026 alone, large-scale synthesis orders increased 18% year-over-year, driven by: (1) late-stage clinical trial supply for ASO and siRNA candidates, (2) commercial launch of new oligonucleotide drugs (e.g., Alnylam’s Amvuttra, Ionis’s olezarsen), (3) CRISPR gene editing therapies requiring large quantities of synthetic guide RNA (gRNA), (4) mRNA vaccine manufacturing (oligo primers for IVT templates), (5) diagnostic kit production (NGS probes, primers), and (6) capacity expansion by CDMOs (e.g., Catalent, Lonza, Samsung Biologics entering the oligo space). Notably, the gram grade segment (gram to kilogram quantities, cGMP-grade) captured 80% of market value (fastest-growing at 15% CAGR, driven by commercial and clinical supply), while microgram grade (research-scale, non-GMP) held 20% share. The commercial segment (pharmaceutical companies, biotech, CDMOs) dominated with 85% share, while academic research held 15%.
Product Definition & Functional Differentiation
Large scale oligonucleotide synthesis service refers to the industrial-scale (gram to kilogram quantities) production of DNA or RNA oligonucleotides under cGMP (current Good Manufacturing Practice) or non-GMP conditions. Unlike research-scale synthesis (microgram to milligram, non-GMP, standard purity, short turnaround), large-scale synthesis is a discrete, high-throughput manufacturing process designed for clinical trials (Phase I-III), commercial drug supply, diagnostic kit production, and industrial applications.
Large Scale vs. Research Scale Synthesis (2026):
| Parameter | Large Scale Synthesis (Gram/Kilogram) | Research Scale Synthesis (Microgram/Milligram) |
|---|---|---|
| Typical quantity | 1 gram to 10+ kilograms | 1 microgram to 100 milligrams |
| Regulatory compliance | cGMP (FDA, EMA, ICH Q7) or non-GMP | Non-GMP (research use only) |
| Purity requirements | >95% (pharmaceutical grade), <99% for critical applications | >85-90% (standard), >95% (PAGE/HPLC purified) |
| Synthesis platform | Large-scale synthesizers (10-200 mmol scale) | Standard synthesizers (0.2-50 µmol scale) |
| Purification | Preparative HPLC, IEX, SEC (high throughput) | Desalting, PAGE, analytical HPLC |
| Quality control | Full release testing (mass spec, HPLC, endotoxin, bioburden, sterility) | MALDI-TOF or LC-MS (limited) |
| Documentation | Batch records, CoA, stability studies, validation | CoA (basic) |
| Lead time | 4-12 weeks (depending on scale and complexity) | 1-2 weeks |
| Price per gram | $1,000-10,000+ (scale-dependent) | $100-500 per mg (research scale) |
| Typical applications | Clinical trials, commercial drug supply, diagnostic kits, industrial enzymes | R&D, screening, validation, early discovery |
Large Scale Synthesis Scales (2026):
| Scale | Typical Quantity | Applications | cGMP | Price Range (USD per gram) | Market Share |
|---|---|---|---|---|---|
| Microgram Grade (Research Scale) | 1 µg – 100 mg | R&D, screening, validation, early discovery | No | $100-500 (per mg) | 20% |
| Gram Grade (Small Scale Production) | 1 g – 100 g | Preclinical studies, Phase I clinical trials, diagnostic kits | Optional (often non-GMP for preclinical) | $1,000-5,000 | 40% |
| Large Scale (Kilogram Production) | 100 g – 10+ kg | Phase II-III clinical trials, commercial supply, industrial applications | Yes (cGMP required) | $5,000-10,000+ | 40% (fastest-growing) |
Key Large Scale Synthesis Technologies (2026):
| Technology | Description | Advantages | Limitations |
|---|---|---|---|
| Solid-Phase Synthesis (SPPS) | Phosphoramidite chemistry on controlled-pore glass (CPG) or polymer supports | Mature, scalable, high purity, automation | High cost per gram (reagents, solvents), waste generation |
| Enzymatic Synthesis | Template-independent polymerase (e.g., terminal deoxynucleotidyl transferase, TdT) | Lower cost, reduced waste, potential for long oligos (>200 nt) | Emerging technology, lower yield, not yet cGMP-compliant at scale |
| Microfluidic Synthesis | Continuous flow synthesis on microfluidic chips | Reduced reagent consumption, faster cycle times | Limited scale (still research stage) |
Industry Segmentation & Recent Adoption Patterns
By Synthesis Scale:
- Gram Grade (1g to 10kg, 80% market value share, fastest-growing at 15% CAGR) – Clinical trials (Phase I-III), commercial drug supply, diagnostic kits, industrial enzymes. cGMP required for clinical/commercial pharma applications.
- Microgram Grade (1µg to 100mg, 20% share) – R&D, screening, validation, early discovery. Non-GMP, research use only.
By Application:
- Commercial (pharmaceutical companies, biotech, CDMOs, diagnostic manufacturers, industrial enzyme producers) – 85% of market, largest segment.
- Academic Research (universities, research institutes, non-profit organizations) – 15% share.
Key Players & Competitive Dynamics (2026 Update)
Leading vendors include: GenScript (USA/China), Biol-Synthesis (USA), Creative Biolabs (USA), Eurofins Genomics (Luxembourg/Germany), Metabion (Germany), Integrated DNA Technologies (IDT, USA, Danaher), Kaneka Eurogentec SA (Belgium), TriLink (USA, Maravai LifeSciences), Synbio Technologies (China), Glen Research (USA), Bachem (Switzerland), Sumitomo Chemical (Japan). IDT (Danaher) and GenScript dominate the large-scale oligonucleotide synthesis market (combined 30-40% share) with global manufacturing facilities, cGMP capabilities, and extensive quality systems. Eurofins Genomics and Metabion are strong European players. Bachem specializes in peptide and oligonucleotide cGMP manufacturing (kilogram scale). TriLink (Maravai) focuses on clean-tag and modified oligonucleotides for diagnostic and therapeutic applications. In 2026, IDT expanded its cGMP oligonucleotide manufacturing capacity with a new 50,000 sq. ft. facility in Coralville, Iowa, dedicated to large-scale synthesis for clinical trials and commercial supply. GenScript launched “GenScript cGMP Oligo Synthesis” platform (gram to kilogram scale, FDA/EMA-compliant, ICH Q7) for ASO, siRNA, and CRISPR gRNA. Bachem announced a $200 million expansion of its oligonucleotide manufacturing capacity (Boulder, Colorado) to meet growing demand for commercial-scale oligos. Synbio Technologies (China) expanded large-scale synthesis capacity (kilogram scale) for Chinese biotech and pharmaceutical companies.
Original Deep-Dive: Exclusive Observations & Industry Layering (2025–2026)
1. Discrete cGMP Manufacturing vs. Research-Scale Synthesis
| Parameter | cGMP Large Scale (Commercial/Clinical) | Non-GMP Research Scale |
|---|---|---|
| Regulatory compliance | FDA 21 CFR Part 210/211, ICH Q7, EMA GMP | None (research use only) |
| Quality system | Change control, validation, deviation management, CAPA | Basic QC |
| Documentation | Batch records, CoA, stability studies, validation reports | CoA only |
| Auditing | Customer audits, regulatory agency inspections | Not applicable |
| Lead time | 8-12 weeks (cGMP) | 1-2 weeks |
| Cost per gram | $5,000-10,000+ | $100-500 per mg |
2. Technical Pain Points & Recent Breakthroughs (2025–2026)
- High cost of large-scale cGMP synthesis: Reagents, solvents, and purification costs scale linearly. New enzymatic synthesis (TdT-based) (Molecular Assemblies, DNA Script, 2025) promises lower cost per gram, reduced waste, and longer oligos (>200 nt). However, cGMP compliance and scale-up are still in development.
- Impurity control (deletions, depurination, modifications) : Large-scale synthesis increases impurity levels (n-1, n-2 deletions, depurination). New advanced purification methods (2D-HPLC, IEX-SEC, simulated moving bed (SMB) chromatography) (Bachem, 2025) achieve >98% purity at kilogram scale.
- Long oligo synthesis (>100 nt) for CRISPR gRNA: Standard solid-phase synthesis has lower yield for >100 nt oligos. New enzymatic synthesis and ligation-based assembly (IDT, 2025) enable high-purity long oligos (200 nt) for CRISPR and gene synthesis.
- GMP capacity constraints (supply chain risk) : Limited cGMP oligo synthesis capacity creates supply chain bottlenecks. New CDMO capacity expansion (Bachem, Lonza, Catalent, Samsung Biologics, 2025-2026) adds 2-3× capacity by 2028.
3. Real-World User Cases (2025–2026)
Case A – Commercial ASO Drug Supply: Ionis Pharmaceuticals (USA) contracted Bachem for large-scale cGMP synthesis of olezarsen (ASO for familial chylomicronemia syndrome) commercial supply (2025). Results: (1) kilogram-scale synthesis; (2) >98% purity; (3) FDA-approved commercial supply; (4) 12-month lead time from order to commercial launch. “Large-scale cGMP oligo synthesis is the bottleneck for commercial ASO supply.”
Case B – CRISPR gRNA for Clinical Trial: CRISPR Therapeutics (Switzerland/USA) contracted IDT for large-scale cGMP synthesis of synthetic gRNA for ex vivo CRISPR therapy (CTX110, cancer trial) (2026). Results: (1) gram-scale gRNA; (2) >95% purity; (3) cGMP-compliant; (4) FDA-approved for clinical trial supply. “Large-scale synthetic gRNA is essential for CRISPR therapy manufacturing.”
Strategic Implications for Stakeholders
For pharmaceutical and biotech executives, large-scale oligonucleotide synthesis service selection depends on: (1) scale (gram vs. kilogram), (2) cGMP compliance (for clinical/commercial), (3) purity (>95-99%), (4) modification capability (2′-OMe, 2′-F, PS, LNA, GalNAc), (5) lead time (4-12 weeks), (6) quality system (ICH Q7, FDA/EMA compliance), (7) capacity (manufacturer backlog), (8) cost ($1,000-10,000+ per gram), (9) IP and confidentiality agreements. For CDMOs, growth opportunities include: (1) cGMP capacity expansion (meet growing clinical and commercial demand), (2) enzymatic synthesis (lower cost, longer oligos), (3) advanced purification (2D-HPLC, SMB, higher purity), (4) long oligo synthesis (>100 nt for CRISPR), (5) conjugation and modification services (GalNAc, lipids, dyes), (6) integrated drug substance + drug product (oligo + formulation), (7) quality by design (QbD) and process analytical technology (PAT) for continuous manufacturing.
Conclusion
The large scale oligonucleotide synthesis service market is growing at 12-15% CAGR, driven by late-stage clinical trials, commercial drug launches, CRISPR therapies, and diagnostic production. Gram grade (80% share, 15% CAGR) dominates and is fastest-growing. Commercial (85% share) is the largest application. IDT, GenScript, Eurofins, Bachem, and TriLink lead the market. As QYResearch’s forthcoming report details, the convergence of cGMP capacity expansion, enzymatic synthesis (lower cost, longer oligos) , advanced purification (2D-HPLC, SMB) , long oligo synthesis (>100 nt for CRISPR) , and integrated drug substance + drug product offerings will continue expanding the category as the critical manufacturing backbone for oligonucleotide therapeutics and diagnostics.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
